Drug intelligence / Profile preview

DC-008

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

DC-008 is an oral small molecule drug that acts as a Tyrosine Kinase 2 (TYK2) inhibitor. It was developed by DICE Therapeutics, a clinical-stage biopharmaceutical company that was acquired by Eli Lilly. The drug is being investigated for the treatment of autoimmune diseases and was in Phase 1 clinical trials at the time of its acquisition.

Targets

TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on DC-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DC-008.

Explore the full profile